AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7817807 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence from alcohol for 1 year
Number of subjects: 30
Study 3287881 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (10-mg intravenous bolus followed by 15 mg/hr intravenous infusion during 72 hours, followed by 4 X 60 mg during 21 days)
Number of subjects: 34
Study 3287881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 30040757 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow group (video game task inducing flow)
Number of subjects: 20
Study 30040757 — intervention group
Group type: COMPARATOR
Intervention: Control group (video game task not inducing flow)
Number of subjects: 20
Study 28029710 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (CONNECT)
Number of subjects: 0
Study 24914489 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster sessions with cognitive techniques
Number of subjects: 44
Study 24914489 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive-behavioral group therapy (CBGT)
Number of subjects: 44
Study 22804715 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise programme
Number of subjects: 44
Study 22804715 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 21908466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets moistened with 3 ml of normal saline
Number of subjects: 42
Study 21908466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets moistened with 3 ml of 5% acetic acid
Number of subjects: 42
Study 21908466 — intervention group
Group type: COMPARATOR
Intervention: Dry tablets
Number of subjects: 42
Study 18288734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of mononuclear bone marrow cells (MBMC)
Number of subjects: 26
Study 16921039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus BCNU plus SRT (Arm C)
Number of subjects: 401
Study 16921039 — intervention group
Group type: COMPARATOR
Intervention: BCNU plus SRT (Arm A)
Number of subjects: 401
Study 16921039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus BCNU plus ART (Arm D)
Number of subjects: 401
Study 16921039 — intervention group
Group type: COMPARATOR
Intervention: BCNU plus ART (Arm B)
Number of subjects: 401
Study 16921039 — intervention group
Group type: COMPARATOR
Intervention: BCNU plus RT (Arms A and B)
Number of subjects: 401
Study 16921039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, BCNU, and RT (Arms C and D)
Number of subjects: 401
Study 12588472 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg b.i.d.
Number of subjects: 3118
Study 12588472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3118
Study 11119395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d
Number of subjects: 2561
Study 11119395 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 2561
Study 11119395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical smears
Number of subjects: 2561
Study 8936545 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 1 mg.kg‐1 without fentanyl
Number of subjects: 127
Study 8936545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam 0.4 mg.kg‐1 without fentanyl
Number of subjects: 127
Study 8936545 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 1 mg.kg‐1 with fentanyl 0.75 microgram.kg‐1 i.v.
Number of subjects: 127
Study 8936545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam 0.4 mg.kg‐1 with fentanyl 0.75 microgram.kg‐1 i.v.
Number of subjects: 127
Study 1556041 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 75
Study 1556041 — intervention group
Group type: EXPERIMENTAL
Intervention: Meprobamate
Number of subjects: 75
Study 1556041 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 75
Study 1556041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 29438373 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg per day, per os; days 1-14; 21 days per cycle)
Number of subjects: 117
Study 29438373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 28865466 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive supervision intervention
Number of subjects: 0
Study 25706092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/r, dasabuvir, and ribavirin for 12 weeks
Number of subjects: 63
Study 25706092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/r, dasabuvir, and ribavirin for 24 weeks
Number of subjects: 63
Study 25706092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/r, dasabuvir, and ribavirin
Number of subjects: 63
Study 23563195 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated tube voltage selection and automated tube current modulation (protocol A)
Number of subjects: 3
Study 23563195 — intervention group
Group type: COMPARATOR
Intervention: Automated tube current modulation alone (protocol B)
Number of subjects: 3
Study 21501950 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 PUFA supplementation
Number of subjects: 702
Study 21501950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study 19362282 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit mesh technique (S)
Number of subjects: 40
Study 19362282 — intervention group
Group type: COMPARATOR
Intervention: Nonslit mesh technique (NS)
Number of subjects: 40
Study 16702370 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cigarette smoking
Number of subjects: 205
Study 16702370 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical cells of unknown significance or squamous intraepithelial lesion
Number of subjects: 205
Study 15353389 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5-1.5 mg/day)
Number of subjects: 120
Study 15353389 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (0.5-1.5 mg/day)
Number of subjects: 120
Study 15353389 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 120
Study 15353389 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 120
Study 11322352 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive heating
Number of subjects: 100
Study 11322352 — intervention group
Group type: COMPARATOR
Intervention: Passive warming
Number of subjects: 100
Study 7966039 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125 levels in peritoneal fluid
Number of subjects: 46
Study 7966039 — intervention group
Group type: COMPARATOR
Intervention: Serum CA-125 levels
Number of subjects: 46
Study 3119647 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG/hMG treatment (2500 IU hCG twice a week + 150 IU hMG three times a week for 13 weeks)
Number of subjects: 39
Study 3119647 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl only, same injection schedule)
Number of subjects: 39
Study 3119647 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG/hMG treatment
Number of subjects: 39
Study 3119647 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl only)
Number of subjects: 39
Study 31801446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver for 1 hour
Number of subjects: 30
Study 31801446 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 30
Study 30153820 — intervention group
Group type: EXPERIMENTAL
Intervention: Vouchers for fruits and vegetables (FV) over a 1 year period
Number of subjects: 92
Study 30153820 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vouchers)
Number of subjects: 92
Study 27926631 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous electrostimulation of the pectoral muscle combined with specific training (group 1)
Number of subjects: 75
Study 27926631 — intervention group
Group type: COMPARATOR
Intervention: Specific training alone (group 2)
Number of subjects: 75
Study 27926631 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment (group 3)
Number of subjects: 75
Study 24084630 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainer (VFR) in the maxilla and a cuspid retainer in the mandible (group V-CTC)
Number of subjects: 75
Study 24084630 — intervention group
Group type: EXPERIMENTAL
Intervention: VFR in the maxilla combined with stripping of the incisors and cuspids in the mandible (group V-S)
Number of subjects: 75
Study 24084630 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated positioner (group P)
Number of subjects: 75
Study 22016099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5145
Study 22016099 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 5145
Study 20526206 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 2536 (200 mg on day 1)
Number of subjects: 95
Study 20526206 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 2536 (50 or 60 mg on days 1 to 3)
Number of subjects: 95
Study 20526206 — intervention group
Group type: COMPARATOR
Intervention: Control (historical placebo)
Number of subjects: 95
Study 18468955 — intervention group
Group type: EXPERIMENTAL
Intervention: 6000 mg chloride potassium dissolved in grape juice for 28 consecutive days
Number of subjects: 32
Study 18468955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16177196 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg calcium as carbonate, 3 times/d with meals)
Number of subjects: 152
Study 16177196 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules identical in appearance
Number of subjects: 152
Study 12668521 — intervention group
Group type: COMPARATOR
Intervention: Mutation-positive patients with Fabry disease
Number of subjects: 30
Study 12668521 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LVH
Number of subjects: 30
Study 10047688 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese Hamster Ovary cell drived HB vaccine (CDV)
Number of subjects: 225
Study 10047688 — intervention group
Group type: COMPARATOR
Intervention: Plasma drived HB vaccine (PDV)
Number of subjects: 225
Study 8721550 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 279
Study 8721550 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ganciclovir
Number of subjects: 279
Study 8721550 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination foscarnet and ganciclovir
Number of subjects: 279
Study 1839125 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (0.4 mg)
Number of subjects: 12
Study 1839125 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (2.0 mg)
Number of subjects: 12
Study 6344896 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid (mean daily dose 278 mg, range 125-500 mg)
Number of subjects: 96
Study 6344896 — intervention group
Group type: COMPARATOR
Intervention: Conventional diuretics (mainly thiazide)
Number of subjects: 96
Study 6344896 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid
Number of subjects: 96
Study 6344896 — intervention group
Group type: COMPARATOR
Intervention: Conventional diuretics
Number of subjects: 96
Study 6344896 — intervention group
Group type: COMPARATOR
Intervention: Tienilic acid and Conventional diuretics
Number of subjects: 96
Study 29300253 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy plus dermal allograft
Number of subjects: 114
Study 29300253 — intervention group
Group type: COMPARATOR
Intervention: Anterior colporrhaphy alone
Number of subjects: 114
Study 27841850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermacyn
Number of subjects: 110
Study 27841850 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole physiological saline
Number of subjects: 110
Study 26554360 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose target-controlled naloxone infusion
Number of subjects: 0
Study 26554360 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study 22733244 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial removable dental prosthesis (PRDP) retained with precision attachments
Number of subjects: 152
Study 22733244 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened dental arch (SDA) concept preserving or restoring a premolar occlusion
Number of subjects: 152
Study 21735946 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational leaflet
Number of subjects: 533
Study 21735946 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 533
Study 19302911 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of anagrelide (2 mg/d, taken as 4 capsules)
Number of subjects: 34
Study 19302911 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of anagrelide
Number of subjects: 34
Study 19302911 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of anagrelide
Number of subjects: 34
Study 17553466 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 40,000 IU
Number of subjects: 23
Study 17553466 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 23
Study 12622306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 0
Study 12622306 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 0
Study 10832808 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg/day)
Number of subjects: 17
Study 10832808 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg/day)
Number of subjects: 17
Study 9322290 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP+Pedvax HIB
Number of subjects: 271
Study 9322290 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-PRP-T
Number of subjects: 271
Study 9322290 — intervention group
Group type: COMPARATOR
Intervention: DTP
Number of subjects: 271
Study 8342236 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person recruitment strategy (standard)
Number of subjects: 852
Study 8342236 — intervention group
Group type: COMPARATOR
Intervention: By-mail recruitment strategy
Number of subjects: 852
Study 2944268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproteronacetate (AndrocurR)
Number of subjects: 0
Study 2944268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose cyproteronacetate plus lisuride (DoperginR)
Number of subjects: 0
Study 31230494 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct release Mg2+ supplement (one phase)
Number of subjects: 0
Study 31230494 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed release Mg2+ supplement (two phases)
Number of subjects: 0
Study 31230494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test products
Number of subjects: 0
Study 30684328 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesitherapy for more than four days
Number of subjects: 40
Study 30684328 — intervention group
Group type: COMPARATOR
Intervention: Kinesitherapy for less than four days
Number of subjects: 40
Study 27504003 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive PCI
Number of subjects: 219
Study 27504003 — intervention group
Group type: COMPARATOR
Intervention: Culprit-artery-only PCI
Number of subjects: 219
Study 24526745 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured intervention with written instructions (SIW)
Number of subjects: 532
Study 24526745 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured intervention with follow‐up visits (SIF)
Number of subjects: 532
Study 24526745 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 532
Study 22313729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 180
Study 22313729 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO) supplementation
Number of subjects: 180
Study 20377925 — intervention group
Group type: EXPERIMENTAL
Intervention: Wagyu beef (100 g)
Number of subjects: 10
Study 20377925 — intervention group
Group type: COMPARATOR
Intervention: Kangaroo meat (100 g)
Number of subjects: 10
Study 18360139 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Maintained Progress Journal
Number of subjects: 91
Study 18360139 — intervention group
Group type: COMPARATOR
Intervention: Usual information (Control)
Number of subjects: 91
Study 16473224 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof Natural IOL
Number of subjects: 297
Study 16473224 — intervention group
Group type: COMPARATOR
Intervention: AcrySof single-piece IOL
Number of subjects: 297
Study 12050252 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily for 2 years
Number of subjects: 65
Study 12050252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 11148939 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized, nonpunitive medication‐use variance process
Number of subjects: 0
Study 11148939 — intervention group
Group type: COMPARATOR
Intervention: Traditional, multitiered incident‐reporting system for medication errors
Number of subjects: 0
Study 9289431 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of ovarian neoplasms
Number of subjects: 40
Study 1917410 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol 370
Number of subjects: 40
Study 1917410 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol 350
Number of subjects: 40
Study 1917410 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate 320
Number of subjects: 40
Study 6120389 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose oral prednisolone with azathioprine
Number of subjects: 72
Study 6120389 — intervention group
Group type: COMPARATOR
Intervention: High dose oral prednisolone with azathioprine
Number of subjects: 72
Study 31296648 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Maintenance (GM)
Number of subjects: 301
Study 31296648 — intervention group
Group type: COMPARATOR
Intervention: Self-Directed Maintenance (SM)
Number of subjects: 301
Study 31296648 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 301
Study 28317511 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly assessed arm (structured interviews, breath alcohol analysis tests, and blood draws conducted quarterly)
Number of subjects: 314
Study 28317511 — intervention group
Group type: COMPARATOR
Intervention: Minimally assessed arm (engaged in procedures only once, at 6 months after baseline)
Number of subjects: 314
Study 26387030 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone-Esmolol (ME)
Number of subjects: 90
Study 24431462 — intervention group
Group type: COMPARATOR
Intervention: C allele carriers (nonrisk‐associated)
Number of subjects: 611
Study 24431462 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls and siblings (C > T/T)
Number of subjects: 611
Study 24431462 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (T/T > C)
Number of subjects: 611
Study 22340989 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 30
Study 22340989 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexamethasone and local betamethasone injected at the tongue base
Number of subjects: 30
Study 23440680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.025-0.3 g/kg/min)
Number of subjects: 0
Study 23440680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17687131 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 3306
Study 17687131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3306
Study 17687131 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059 (among patients treated with alteplase)
Number of subjects: 3306
Study 17687131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (among patients treated with alteplase)
Number of subjects: 3306
Study 16291413 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg QD for 10 days during the second cycle
Number of subjects: 24
Study 16291413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12479423 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with a 3 ml h(‐1) continuous infusion of fentanyl (2 microg) and bupivacaine (0.125%) for the first 3 days, with patient-controlled analgesia allowing an additional 5 ml of the same solution when pain score > 4.
Number of subjects: 20
Study 12479423 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group with no epidural analgesia).
Number of subjects: 20
Study 12479423 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine (0.125%) after 3 days.
Number of subjects: 20
Study 9661553 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 36
Study 9661553 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic-femoral nerve block
Number of subjects: 36
Study 9661553 — intervention group
Group type: COMPARATOR
Intervention: Sham nerve block
Number of subjects: 36
Study 9661553 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (femoral and sciatic)
Number of subjects: 36
Study 9661553 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks
Number of subjects: 36
Study 7629581 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 1: infusion of 201Tl (111 MBq), insulin (5 U), potassium (10 mEq) in 10% glucose solution (250 ml)
Number of subjects: 30
Study 7629581 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 2: infusion of 201Tl (111 MBq), potassium (10 mEq), insulin (5 U) in 5% glucose (250 ml)
Number of subjects: 30
Study 7629581 — intervention group
Group type: COMPARATOR
Intervention: Control: stress and 3-hr reinjection images (Protocol 1)
Number of subjects: 30
Study 2199721 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoptin
Number of subjects: 0
Study 2199721 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsidian
Number of subjects: 0
Study 7033847 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg twice daily for 14 days
Number of subjects: 40
Study 7033847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31262846 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Consultations (VC)
Number of subjects: 149